Company Description
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel.
The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer.
The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute.
The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.
Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
| Country | Australia |
| Founded | 1994 |
| IPO Date | Jan 6, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | John Friend |
Contact Details
Address: Three International Towers, Level 24 Sydney, NSW 2000 Australia | |
| Phone | 61 2 9472 4101 |
| Website | kaziatherapeutics.com |
Stock Details
| Ticker Symbol | KZIA |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| CIK Code | 0001055886 |
| CUSIP Number | 48669G303 |
| ISIN Number | US48669G3039 |
| SIC Code | 8880 |
Key Executives
| Name | Position |
|---|---|
| Dr. John Edwin Friend II, M.D. | Chief Executive Officer |
| Jeffrey Bonacorda | Vice President of Finance and Controller |
| Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAIC | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2025 | 424B3 | Prospectus |
| Oct 16, 2024 | 424B3 | Prospectus |
| Oct 16, 2024 | 424B3 | Prospectus |
| Oct 16, 2024 | 424B3 | Prospectus |
| Nov 21, 2017 | 424B3 | Prospectus |
| Nov 17, 2017 | 424B3 | Prospectus |
| Jul 11, 2017 | 424B3 | Prospectus |
| Jun 6, 2016 | F-6 POS | Post-effective amendments for immediately effective filing |